Apr.  Completion of AXL inhibitor's Phase 1a clinical trial for solid tumor drug candidate

Aug.  Lazertinib with amivantamab approved by FDA for NSCLC

Mar. Cevidoplenib granted Orphan Drug Designation by FDA for ITP

Sep. Approval for Phase 1a/1b clinical trial of anti-Tau antibody for Alzheimer’s disease

Jul. Completion of SYK inhibitor’s Phase 2 clinical trial for ITP

Jan. Co-development agreement for BRVT121 and BRVT221 (Biorevert Inc.)

Mar. Co-development agreement for EP2/4 program (Kanaph Therapeutics)
Jan. Initiation of AXL inhibitor's Phase 1 clinical trial for solid tumor drug candidate

Mar. Completion of SYK inhibitor's FDA Phase 2a clinical trial for Reumatoid Arthritis

Feb. Joint R&D agreement for LSD1 program (Beactica Therapeutics AB)

Oct. Co-development agreement for ADEL-Y01 (ADEL Inc.)

Oct. Established Ectodor Therapeutics Inc.

Mar. Dr. Yoon Taeyoung inaugurated as Separate CEO

Oct. Initiation of SYK inhibitor's Phase 2 clinical trial for ITP drug candidate

Nov. L/O of EGFR-Targeted Anti-Cancer Drug (Yuhan yo Janssen Biotech.)

Oct. Drug candidate for Reumotoid Arthritis selected as KDDF sponsored Project (Phase 2 clinical trial)

Dec. Commencement of Phase 1 clinical trial of FLT3-Targeted drug candidate for AML

Jul. Completion of SYK inhibitor's FDA Phase 1 clinical trial for Reumatoid Arthritis in US

Oct. Approval for Phase 1 clinical trial of FLT3-Targeted drug candidate fot AML

Oct. IND and CTA of FLT3, AML drug

Apr. GENOSCO separated into R&D company (Moved to Head quarter in Boston)

Jan. Selected for Korea Drug Development Fund (KDDF) project Development of SYK inhibitor for Rheumatoid Arthritis

Dec. Complete in Pre-clinical study for AML drug

Sep. IND and CTA of SYK, inhibitor Rheumatoid Arthritis

Jul. Licensing Out EGFR, non-small-cell-lung-cancer drug candidate

Apr. Porcine pericardium membrane LysoGide approved and production begins

Jun. Selected for Ministry of Health & Welfare’s R&D project Development of FLT3 inhibitor for the treatment of acute myeloid leukemia

May Selected for Korea Drug Development Fund (KDDF) project Development of SYK inhibitor for rheumatoid Arthritis

Apr. Bone graft BioCera-F approved by KFDA and production begins

Oct. Ministry of Science, ICT and future planning-Development of Novel Drug for Parkinson’s disease

May AML drug pre-clinical test

Aug. R&D Center moved into Korea Bio Park and expanded to become Oscotec Central R&D Center

Jun. Commercial production and sales of InduCera

Oct. KFDA approval of AIF, compound of 3 herbal ingredients, as joint health supplement

Aug. KFDA approval of InduCera, dual coated bone graft

Jun. Min. of knowledge & Economy grant on ODS project for int’l collaboration R&D

May. Fund of Ministry For Health, Wel1 re And Family Affairs for the clirical study of OCT-1547, new drug caididate for the treatment of osteoporosis

May. IND and CTA of OCT-1547, new drug candidate lbr the treatment of osteoporosis
Mar. Renaming of OCT USA Inc. – GENOSCO

Dec. Fund of Small And Medium Business Administration for the new drug development for the treatment of arthritis through olecular design

Nov. Fund of Ministry Of Education, Science And Technology kr the new drug development for the treatment of theumatoid arthritis

Sep. Collaborative Research Agreement for the new drug development for the treatment of osteoporosis with ChiKiren’s Hospital Boston, the primary pediatric teaching hospital of Harvard Medical School

Jun. KGMP of Bone Graft Material

Jan. KOSDAQ(Korean Security Dealers Automated Quotation) listing

May. Launching SynCera, a bone graft material which has dual porosities; macropore and micropore

May. Foreign Capital Investment through JAIC

Nov. Foreign Capital Investment agreement with Roberts Mitani, LLC

Jun. BBP(Bovine Bone Powder) Obtained FDA (USA) Approval

Dec. Establishment of a strategic partnership with KT&G. Received Capital Investment from KT&G

Dec. Designated as chief research institute in the 2nd materials and components development project, 2003

Jul. Receiving ‘Excellent platform technology developer’ award in NEWTECH KOREA2001

Mar. Relocation to new Headquarters

Dec. Establishment of OCT USA

Apr. Established affiliated research institute of OCT USA

Mar. KT Certification, Excellent Korean Technology, by the Ministry of Science & Technology

Dec. Obtained the manufacturing and itemization authorization for bone transplant material from the KFDA (Korean Food & Drug Administration)

Aug. Selected as an Excellent Technology Venture Company

Jun. Company name changed to Oscotec Inc

Dec. Establishment of Oscotec Co., Ltd, within Dankook University

Sep. Selected as a SME Venture company eligible to receive funding to establish a company by the Small Business Corporation